藥物動力學/毒性研究


Webinar Bios

Bio - Dave

David Stresser, Ph.D. Program Manager / BD Gentest SM Contract Research Services

Dr. David Stresser has over 13 years experience with BD, including experience as a Study Director in the areas of CYP inhibition, induction, and metabolism. Previously, David was a post-doctoral associate at the University of Massachusetts Medical School in Worcester, MA in the laboratory of Dr. David Kupfer. He has been an invited speaker at various international meetings and universities, most recently at DDI-2011 in Seattle. Dr. Stresser has authored and co-authored 35 peer-reviewed articles and book chapters in the field of drug metabolism.

Bio - George

George Zhang, Ph.D. Study Director

With over 15 years of research experience, Dr. George Zhang’s expertise spans the areas of drug metabolism, enzyme induction, and toxicity using in vitro models such as human hepatocytes. Prior to joining BD Biosciences, George investigated oxidative stress-induced hepatocyte toxicity and cytoprotection as an Assistant Research Professor at Washington State University. He received his Ph.D. in Pharmacology and Toxicology from the University of Liverpool, UK. George also completed additional post-doctoral training on oxidative stress in myocardial ischemia and reperfusion at the University of Leicester, UK. He has authored and co-authored over 35 peer-reviewed papers in the areas of cytochrome P450 induction, oxidative stress and cytoprotection.

Bio - Chris

Chris Patten, Ph.D. Program Manager / Research & Development

Dr. Christopher Patten has over 20 years experience in drug metabolism. He is responsible for some of the early work on P450 purification, as well as cloning and expressing human CYP450s and UDP-glucuronosyltransferases. Dr. Patten began his P450 studies as a Visiting Scientist at the National Institute of Health. He further pursued his interest in P450 enzymes as a Postdoctoral Fellow at Sandoz Pharmaceuticals Corporation, established a baculovirus-insect cell expression system for production of large quantities of human P450 enzymes, and later as a Research Associate at the American Health Foundation and University of Minnesota Cancer Center, isolating and expressing P450 genes involved in carcinogen activation in rat and human esophagus. Dr. Patten has authored and co-authored 33 publications in the field of drug metabolism.

Bio - Na

Na Li, Ph.D. Staff Scientist

Dr. Na Li received her B.S degree in Biology from Fudan University, Shanghai, China, and her Ph.D. in Pharmacology from Dartmouth Medical School, Hanover, NH. Prior to joining BD, Dr. Na Li conducted postdoctoral training on drug transporters at Pfizer Inc., St. Louis with the Pharmacokinetics, Dynamics & Metabolism (PDM) organization. Her major research focus is on drug transporters, including interspecies differences in hepatobiliary transporters, transporter quantification, and in vitro to in vivo extrapolation of drug pharmacokinetics. At BD, Dr. Li contributes her expertise in in vitro drug transporter technology and its application in drug ADME. She has authored and co-authored 12 peer-reviewed publications in the area of drug transporter.

Bio - Charlie

Charlie Crespi Ph.D. Vice President - Discovery Labware

Dr. Crespi is currently Vice President for the Discovery Labware unit of BD Biosciences. He received his PhD in toxicology from the Massachusetts Institute of Technology. In the early 1980s, Dr. Crespi and associates founded GENTEST Corporation, a company that became a leader in developing in vitro systems for the study of drug metabolism and safety. GENTEST Corporation was acquired by BD in 2001. Dr. Crespi has been a member of the International Society for the Study of Xenobiotics (ISSX) since the early 1990s and is currently serving as Treasurer of the society. Dr. Crespi is also a member of American Association of Pharmaceutical Scientists (AAPS), and Society of Toxicology (SOT). He currently serves as Chairperson of the Steering Committee for the New England Drug Metabolism Discussion Group.